Zacks Research Has Weak Estimate for Danaher FY2024 Earnings

Danaher Co. (NYSE:DHR) – Zacks Research decreased their FY2024 earnings per share estimates for Danaher in a report released on Tuesday, November 12th. Zacks Research analyst R. Department now expects that the conglomerate will post earnings of $7.49 per share for the year, down from their previous estimate of $7.56. The consensus estimate for Danaher’s current full-year earnings is $7.51 per share. Zacks Research also issued estimates for Danaher’s Q4 2024 earnings at $2.14 EPS, Q1 2025 earnings at $2.05 EPS, Q2 2025 earnings at $1.91 EPS, Q3 2025 earnings at $1.94 EPS, Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $8.24 EPS, Q1 2026 earnings at $2.21 EPS, Q2 2026 earnings at $2.25 EPS and FY2026 earnings at $9.28 EPS.

A number of other equities analysts have also weighed in on the company. UBS Group lowered their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Robert W. Baird lowered their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Bank of America boosted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Evercore ISI upped their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, KeyCorp upped their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Stock Performance

NYSE DHR opened at $230.51 on Thursday. The stock’s fifty day moving average is $262.91 and its two-hundred day moving average is $260.49. The firm has a market capitalization of $166.49 billion, a P/E ratio of 45.00, a price-to-earnings-growth ratio of 4.44 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher has a fifty-two week low of $206.30 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the business earned $2.02 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.47%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 18.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 11.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Danaher by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the period. FMR LLC boosted its position in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares during the period. Swedbank AB acquired a new stake in shares of Danaher in the 1st quarter valued at about $676,545,000. TD Asset Management Inc boosted its position in shares of Danaher by 99.0% in the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after purchasing an additional 675,952 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its position in shares of Danaher by 22.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after purchasing an additional 563,546 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.